Citations

Clear

439 citation(s) found for "Stone, M".

Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3
Fussner, Lynn A. , Hummel, Amber M., Schroeder, Darrell R. , Cartin‐Ceba, Rodrigo , Snyder, Melissa R. , Hoffman, Gary S., Kallenberg, Cees G. M., Langford, Carol A. , Seo, Philip , Clair, E. William St. , Tchao, Nadia K., Stone, John H., Silva, Francisco , Merkel, Peter A. , Monach, Paul A. , Spiera, Robert , Specks, Ulrich , Schroeder, Darrell

Mayo Clinic

Arthritis & Rheumatology | February 16, 2016 | Volume: 68 | Issue: 7 | Pages: 1700-1710

10.1002/art.39637 | PMID 26882078 Get It

Objective Relapse following remission is common in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV), particularly with ANCAs directed at proteinase 3 (PR3). This study was undertaken to evaluate the association of an increase in PR3‐ANCA level with subsequent relapse. Methods Data from the Rituximab versus Cyclophosphamide for ANCA‐Associated Vasculitis (RAVE) trial were used. Starting from the time of achieving complete remission, serial measurements by direct and capture enzyme‐linked immunosorbent assays (ELISAs) were analyzed in 93 patients with PR3‐ANCA, using Cox proportional hazards regression. Results An increase in PR3‐ANCA level was identified in 58 of 93 subjects (62.4%) by direct ELISA and in 59 of 93 (63.4%) by capture ELISA. Relapses occurred in 55 of 93 subjects (59.1%), with 25 and 21 occurring within 1 year after an increase by direct ELISA and capture ELISA, respectively. An increase by direct ELISA was associated with subsequent severe relapses (hazard ratio [HR] 4.57; P < 0.001), particularly in patients presenting with renal involvement (HR 7.94; P < 0.001) and alveolar hemorrhage (HR 24.19; P < 0.001). Both assays identified increased risk for severe relapse in the rituximab group (HR 5.80; P = 0.002 for direct ELISA and HR 4.54; P = 0.007 for capture ELISA) but not the cyclophosphamide/azathioprine group ( P = 0.103 and P = 0.197, respectively). Conclusion The association of an increase in PR3‐ANCA level with the risk of subsequent relapse is partially affected by the PR3‐ANCA detection methodology, disease phenotype, and remission induction treatment. An increase in PR3‐ANCA level during complete remission conveys an increased risk of relapse, particularly severe relapse, among patients with renal involvement or alveolar hemorrhage and those treated with rituximab. Serial measurements of PR3‐ANCA may be informative in this subset of patients, but the risk of relapse must be weighed carefully against the risks associated with therapy.
Prediction of 1‐year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient‐level pooled analysis from three randomized trials
Yu, Jennifer , Clayton, Tim , Brodie, Bruce R. , Witzenbichler, Bernhard , Deliargyris, Efthymios , Pocock, Stuart , Stone, Gregg W. , Dangas, George , Mehran, Roxana , Gibson, C. Michael , Lincoff, A. Michael , Gersh, Bernard J.

Mayo Clinic

Catheterization and Cardiovascular Interventions | December 1, 2015 | Volume: 87 | Issue: 3 | Pages: 391-400

10.1002/ccd.26146 | PMID 26624854 Get It

Objectives: We aimed to construct a predictive model for one‐year mortality in patients undergoing invasive coronary evaluation and to examine the impact of bivalirudin on survival according to the level of baseline risk.Background: Compared to heparin plus GP IIb/IIIa inhibitors (HEP/GPI), bivalirudin decreases bleeding complications in a range of clinical presentations. The impact of preprocedural risk assessment on survival and whether this is modified by bivalirudin, has not been investigated in detail.Methods: We examined patient‐level data from the REPLACE‐2, ACUITY, and HORIZONS‐AMI trials (n = 18,819) to construct a risk‐adjusted mortality model using baseline clinical variables.Results: One‐year mortality occurred in 287 patients (3.1%) assigned to bivalirudin and 336 patients (3.6%) assigned to HEP/GPI (HR 0.85; 95% CI, 0.73–1.00; P = 0.048). Using 11 highly significant predictors of mortality, we developed an integer‐risk score to classify patients into risk tertiles. High‐risk patients had a rate of 1‐year mortality over 9‐fold greater than low‐risk patients. Consequently, the absolute mortality reduction attributed to bivalirudin was more marked in high‐risk patients: 3.1% (−0.8% to 7.0%) in the overall cohort, 4.8% (0.5% to 9.2%) in the PCI cohort (P‐interaction versus intermediate and low risk categories, 0.09 and P = 0.02, respectively).Conclusions: In patients undergoing invasive coronary evaluation, 1‐year mortality can be predicted using baseline variables. Bivalirudin treatment (versus HEP/GPI) conferred a survival benefit. © 2015 Wiley Periodicals, Inc.
Characterization of Urinary Stone Composition by Use of Third-Generation Dual-Source Dual-Energy CT With Increased Spectral Separation
Duan, Xinhui , Li, Zhoubo , Yu, Lifeng , Halaweish, Ahmed F., Yu, Lifeng , Leng, Shuai , Fletcher, Joel G. , McCollough, Cynthia H.

Mayo Clinic

American Journal of Roentgenology | November 20, 2015 | Volume: 205 | Issue: 6 | Pages: 1203-1207

10.2214/ajr.15.14348 | PMID 26587926 Get It

Natural History, Complications and Re-Intervention Rates of Asymptomatic Residual Stone Fragments after Ureteroscopy: a Report from the EDGE Research Consortium
Brotherhood, Hilary, Sur, Roger L. , Wang, An Qi, Knudsen, Bodo E. , Yong, Courtney , Marien, Tracy , Miller, Nicole L. , Krambeck, Amy E. , Charchenko, Cameron, Humphreys, Mitchell R. , Chew, Ben H. , Miller, Nicole L

Mayo Clinic

Journal of Urology | November 14, 2015 | Volume: 195 | Issue: 4 Part 1 | Pages: 982-986

10.1016/j.juro.2015.11.009 | PMID 26585680 Get It

U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin
Snydman, David R. , McDermott, L. A., Jacobus, N V, Thorpe, Cheleste M. , Stone, S. , Jenkins, Stephen G., Goldstein, Ellie J. C. , Patel, Robin , Forbes, Betty A., Mirrett, S, Johnson, Stuart , Gerding, Dale N. , Patel, Robin , Snydman, D R

Mayo Clinic

Antimicrobial Agents and Chemotherapy | August 4, 2015 | Volume: 59 | Issue: 10 | Pages: 6437-6443

10.1128/aac.00845-15 | PMID 26239985 Get It

ABSTRACT In 2011 a surveillance study for the susceptibility to fidaxomicin and epidemiology of Clostridium difficile isolates in the United States was undertaken in seven geographically dispersed medical centers. This report encompasses baseline surveillance in 2011 and 2012 on 925 isolates. A convenience sample of C. difficile isolates or toxin positive stools from patients were referred to a central laboratory. Antimicrobial susceptibility was determined by agar dilution (CLSI M11-A8). Clinical and Laboratory Standards Institute (CLSI), Food and Drug Administration, or European Union of Clinical Antimicrobial Susceptibility Testing (EUCAST) breakpoints were applied where applicable. Toxin gene profiles were characterized by multiplex PCR on each isolate. A random sample of 322 strains, stratified by institution, underwent restriction endonuclease analysis (REA). The fidaxomicin MIC 90 was 0.5 μg/ml for all isolates regardless of REA type or toxin gene profile, and all isolates were inhibited at ≤1.0 μg/ml. By REA typing, BI strains represented 25.5% of the isolates. The toxin gene profile of tcdA , tcdB , and cdtA/B positive with a tcdC 18-bp deletion correlated with BI REA group. Moxifloxacin and clindamycin resistance was increased among either BI or binary toxin-positive isolates. Metronidazole and vancomycin showed reduced susceptibility (EUCAST criteria) in these isolates. Geographic variations in susceptibility, REA group and binary toxin gene presence were observed. Fidaxomicin activity against C. difficile isolated in a national surveillance study did not change more than 1 year after licensure. This analysis provides baseline results for future comparisons.
Radiation Dose Reduction in Dual-Energy CT: Does It Affect the Accuracy of Urinary Stone Characterization?
Qu, Mingliang , Yu, Lifeng , Cardona, Daniel Gomez , Liu, Yu , Duan, Xinhui , Ai, Songtao , Shiung, Maria, Yu, Lifeng , Leng, Shuai , McCollough, Cynthia H.

Mayo Clinic

American Journal of Roentgenology | July 23, 2015 | Volume: 205 | Issue: 2 | Pages: W172-W176

10.2214/ajr.14.12929 | PMID 26204304 Get It

A 53‐Year‐Old Man With Dysuria, Pyuria, and Genital Ulcers
Jimenez, Xavier , Psutka, Sarah P. , Stone, John H. , Carruthers, Mollie N. , Psutka, Sarah P

Mayo Clinic

Arthritis Care & Research | May 18, 2015 | Volume: 68 | Issue: 9 | Pages: 1371-1377

10.1002/acr.22617 | PMID 25989159 Get It

Neutrophil‐Related Gene Expression and Low‐Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Grayson, Peter C. , Xu, Lijing, Lim, Noha , Gao, Zhong, Asare, Adam L. , Stone, John H., Seo, Philip , Langford, Carol A. , Hoffman, Gary S., Kallenberg, Cees G. M., Clair, E. William St. , Tchao, Nadia K., Ytterberg, Steven R. , Phippard, Deborah, Kaplan, Mariana J. , Carmona‐Rivera, Carmelo , Specks, Ulrich , Spiera, Robert , Merkel, Peter A. , Monach, Paul A. , Asare, Adam L

Mayo Clinic

Arthritis & Rheumatology | April 17, 2015 | Volume: 67 | Issue: 7 | Pages: 1922-1932

10.1002/art.39153 | PMID 25891759 Get It

ObjectiveTo discover biomarkers involved in the pathophysiology of antineutrophil cytoplasmic antibody–associated vasculitis (AAV) and to determine whether low‐density granulocytes (LDGs) contribute to gene expression signatures in AAV.MethodsThe source of clinical data and linked biologic specimens was a randomized controlled treatment trial in AAV. RNA sequencing of whole blood from patients with AAV was performed during active disease at the baseline visit and during remission 6 months later. Gene expression was compared between patients who met versus those who did not meet the primary trial outcome of clinical remission at 6 months (responders versus nonresponders). Measurement of neutrophil‐related gene expression was confirmed in peripheral blood mononuclear cells (PBMCs) to validate the findings in whole blood. A negative‐selection strategy isolated LDGs from PBMC fractions.ResultsDifferential expression between responders (n = 77) and nonresponders (n = 35) was detected in 2,346 transcripts at the baseline visit (P < 0.05). Unsupervised hierarchical clustering demonstrated a cluster of granulocyte‐related genes, including myeloperoxidase (MPO) and proteinase 3 (PR3). A granulocyte multigene composite score was significantly higher in nonresponders than in responders (P < 0.01) and during active disease than during remission (P < 0.01). This signature strongly overlapped an LDG signature identified previously in lupus (false discovery rate by gene set enrichment analysis <0.01). Transcription of PR3 measured in PBMCs was associated with active disease and treatment response (P < 0.01). LDGs isolated from patients with AAV spontaneously formed neutrophil extracellular traps containing PR3 and MPO.ConclusionIn AAV, increased expression of a granulocyte gene signature is associated with disease activity and decreased response to treatment. The source of this signature is likely LDGs, a potentially pathogenic cell type in AAV.
Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures
Stone, Jennifer , Thompson, Deborah J. , dos‐Santos‐Silva, Isabel , Lindström, Sara , Hazra, Aditi , Li, Jingmei , Eriksson, Louise , Jensen, Matt , Cunningham, Julie M. , Purrington, Kristen S. , Brown, Judith, Leyland, Jean, Warren, Ruth , Luben, Robert , Smith, Paula , Jud, Sebastian M. , Heusinger, Katharina, Beckmann, Matthias W. , Douglas, Julie A. , Shah, Kaanan P., Chan, Heang‐Ping , Helvie, Mark A. , Kolonel, Laurence N. , Woolcott, Christy , Haiman, Christopher A. , Giles, Graham G. , Baglietto, Laura , Krishnan, Kavitha , Southey, Melissa C. , Apicella, Carmel, Andrulis, Irene L. , Knight, Julia A. , Ursin, Giske , Alnæs, Grethe I.G., Kristensen, Vessela N. , Børresen‐Dale, Anne‐Lise , Bolla, Manjeet K. , Wang, Qin , Michailidou, Kyriaki , Simard, Jacques , Dunning, Alison M. , Easton, Douglas F. , Fasching, Peter A. , Vachon, Celine M. , Durocher, Francine , Cunningham, Julie, Scott, Christopher G. , Tamimi, Rulla M. , Kraft, Peter , Czene, Kamila , Hall, Per N , Olson, Janet E. , Couch, Fergus J. , Khaw, Kay‐Tee , Wareham, Nicholas J. , Marchand, Loı̈c Le , Maskarinec, Gertraud , Gram, Inger Torhild , Dennis, Joe , Pharoah, Paul D.P. , Pankratz, V. Shane , Hopper, John L. , Vachon, Celine M. , Luben, Robert N , Giles, Graham G , Southey, Melissa C , Dunning, Alison M , Li, Jingmei , Michailidou, Kyriaki , Simard, Jacques , Stone, Jennifer , Baglietto, Laura , Purrington, Kristen S , Chan, Heang-Ping

Mayo Clinic

Cancer Research | April 10, 2015 | Volume: 75 | Issue: 12 | Pages: 2457-2467

10.1158/0008-5472.can-14-2012 | PMID 25862352 Get It

Abstract Mammographic density measures adjusted for age and body mass index (BMI) are heritable predictors of breast cancer risk, but few mammographic density-associated genetic variants have been identified. Using data for 10,727 women from two international consortia, we estimated associations between 77 common breast cancer susceptibility variants and absolute dense area, percent dense area and absolute nondense area adjusted for study, age, and BMI using mixed linear modeling. We found strong support for established associations between rs10995190 (in the region of ZNF365), rs2046210 (ESR1), and rs3817198 (LSP1) and adjusted absolute and percent dense areas (all P &lt; 10−5). Of 41 recently discovered breast cancer susceptibility variants, associations were found between rs1432679 (EBF1), rs17817449 (MIR1972-2: FTO), rs12710696 (2p24.1), and rs3757318 (ESR1) and adjusted absolute and percent dense areas, respectively. There were associations between rs6001930 (MKL1) and both adjusted absolute dense and nondense areas, and between rs17356907 (NTN4) and adjusted absolute nondense area. Trends in all but two associations were consistent with those for breast cancer risk. Results suggested that 18% of breast cancer susceptibility variants were associated with at least one mammographic density measure. Genetic variants at multiple loci were associated with both breast cancer risk and the mammographic density measures. Further understanding of the underlying mechanisms at these loci could help identify etiologic pathways implicated in how mammographic density predicts breast cancer risk. Cancer Res; 75(12); 2457–67. ©2015 AACR.